肺炎治疗市场－全球产业规模、份额、趋势、机会和预测，按感染类型、类型、药物类别、最终用户、地区和竞争格局划分，2020-2030年预测

全球肺炎治疗药物市场规模将从2024年的29.1亿美元成长到2030年的45.6亿美元，复合年增长率达7.76%。肺炎治疗药物涵盖一系列旨在对抗肺炎的药物介入和医疗手段。肺炎是一种严重的呼吸道感染，其特征是肺部气囊发炎。全球市场扩张的主要驱动力是呼吸系统疾病持续高发，尤其是在老年人和幼儿等易感人群中。

主要市场驱动因素

全球肺炎治疗市场的主要驱动力是全球肺炎发病率的不断上升以及抗生素抗药性威胁的日益加剧。全球肺炎高发生率持续居高不下，导致患者群体不断扩大，需要从初始抗菌治疗到支持性护理等各种治疗干预措施。

主要市场挑战

新型广谱抗生素和抗病毒药物所需的大量资金投入和严格的监管审批流程，严重阻碍了全球肺炎治疗市场的成长。从最初的研发到产品上市，漫长而复杂的过程需要大量资金，这可能会阻碍潜在的创新者，并降低製药公司投资这一关键领域的动机。

主要市场趋势

单株抗体和宿主导向疗法等新型治疗手段的出现，代表着全球肺炎治疗市场的显着成长趋势。这些创新疗法突破了传统抗生素的限制，提供了对抗感染的新机制，并有助于应对抗菌素抗药性这一迫切挑战。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球肺炎治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依感染类型（院内获得性肺炎[HAP]、社区型肺炎[CAP]、呼吸器相关性肺炎[VAP]）
  • 依类型（药物、预防性疫苗、氧气治疗）
  • 依药物类别（抗菌药物、抗病毒药物、抗真菌药物）
  • 按最终使用者（医院和诊所、门诊手术中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美肺炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肺炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肺炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肺炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲肺炎治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球肺炎治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Pfizer Inc.
• AstraZeneca Plc.
• Eli Lilly & company
• F. Hoffmann-La Roche Ltd.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited

第十六章：策略建议

第17章调查会社について・免责事项

The Global Pneumonia Therapeutics Market will grow from USD 2.91 Billion in 2024 to USD 4.56 Billion by 2030 at a 7.76% CAGR. Pneumonia therapeutics comprise a class of pharmaceutical interventions and medical treatments aimed at combating pneumonia, a serious respiratory infection characterized by inflammation of the lung's air sacs. The global market's expansion is fundamentally propelled by the persistent high global incidence of respiratory illnesses, particularly among susceptible demographics such as the elderly and young children.

Key Market Drivers

The global pneumonia therapeutics market is significantly driven by the increasing worldwide incidence of pneumonia and the escalating threat of antibiotic resistance. The persistent high global incidence of pneumonia creates a continuous and expanding patient population requiring various therapeutic interventions, from initial antimicrobial treatments to supportive care. This rising burden necessitates robust market supply and fosters demand for improved treatment efficacy and accessibility across diverse demographics.

Key Market Challenges

The substantial financial investment and stringent regulatory approval processes for new broad-spectrum antibiotics and antiviral treatments pose a significant impediment to the growth of the global pneumonia therapeutics market. The lengthy and complex journey from initial research to market entry demands considerable capital, which can deter potential innovators and reduce the incentive for pharmaceutical companies to invest in this critical area. This is particularly relevant for novel agents, where the inherent risk of failure is high, and the return on investment can be uncertain due to evolving pathogen resistance and specific treatment protocols aimed at preserving drug efficacy.

Key Market Trends

The emergence of novel therapeutic classes, such as monoclonal antibodies and host-directed therapies, represents a significant growth trend in the global pneumonia therapeutics market. These innovative treatments move beyond traditional antibiotics, offering new mechanisms to combat infection and address the pressing challenge of antimicrobial resistance. Monoclonal antibodies provide targeted immune responses, while host-directed therapies modulate the body's own defense mechanisms, potentially leading to broader efficacy and reduced development of resistance.

Key Market Players

• Pfizer Inc.
• AstraZeneca Plc.
• Eli Lilly & company
• F. Hoffmann-La Roche Ltd.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Limited

Report Scope:

In this report, the Global Pneumonia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumonia Therapeutics Market, By Infection Type:

• Hospital-acquired Pneumonia [HAP]
• Community-acquired Pneumonia [CAP]
• Ventilator-associated Pneumonia [VAP]

Pneumonia Therapeutics Market, By Type:

• Drugs
• Preventive Vaccines
• Oxygen Therapy

Pneumonia Therapeutics Market, By Drug Class:

• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Pneumonia Therapeutics Market, By End User:

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

Pneumonia Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Pneumonia Therapeutics Market.

Available Customizations:

Global Pneumonia Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumonia Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP])
  • 5.2.2. By Type (Drugs, Preventive Vaccines, Oxygen Therapy)
  • 5.2.3. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs)
  • 5.2.4. By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Pneumonia Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Infection Type
  • 6.2.2. By Type
  • 6.2.3. By Drug Class
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pneumonia Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Infection Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Pneumonia Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Infection Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Pneumonia Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Infection Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By End User

7. Europe Pneumonia Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Infection Type
  • 7.2.2. By Type
  • 7.2.3. By Drug Class
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pneumonia Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Infection Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By End User
  • 7.3.2. France Pneumonia Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Infection Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Pneumonia Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Infection Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Pneumonia Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Infection Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Drug Class
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Pneumonia Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Infection Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Drug Class
      • 7.3.5.2.4. By End User

8. Asia Pacific Pneumonia Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Infection Type
  • 8.2.2. By Type
  • 8.2.3. By Drug Class
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pneumonia Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Infection Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By End User
  • 8.3.2. India Pneumonia Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Infection Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Pneumonia Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Infection Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Pneumonia Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Infection Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Drug Class
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Pneumonia Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Infection Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Drug Class
      • 8.3.5.2.4. By End User

9. Middle East & Africa Pneumonia Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Infection Type
  • 9.2.2. By Type
  • 9.2.3. By Drug Class
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pneumonia Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Infection Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Pneumonia Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Infection Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Pneumonia Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Infection Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By End User

10. South America Pneumonia Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Infection Type
  • 10.2.2. By Type
  • 10.2.3. By Drug Class
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pneumonia Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Infection Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Drug Class
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Pneumonia Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Infection Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Drug Class
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Pneumonia Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Infection Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Drug Class
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pneumonia Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca Plc.
• 15.3. Eli Lilly & company
• 15.4. F. Hoffmann-La Roche Ltd.
• 15.5. Viatris Inc.
• 15.6. Teva Pharmaceutical Industries Ltd.
• 15.7. Sanofi SA
• 15.8. Novartis AG
• 15.9. Sun Pharmaceutical Industries Ltd.
• 15.10. Aurobindo Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer